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Abstract 
Background and aims: The relationship between lipoprotein levels, low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and clinical outcome after 
intracerebral hemorrhage (ICH) remains controversial. We sought to evaluate the association of 
lipoprotein cholesterol levels and statin dosage with clinical and neuroimaging outcomes in 
patients with ICH.  
Methods: Data on consecutive patients hospitalized with spontaneous acute ICH was 
prospectively collected over a 5-year period and retrospectively analyzed. Demographic 
characteristics, clinical severity documented by NIHSS-score and ICH-score, neuroimaging 
parameters, pre-hospital statin use and doses, and LDL-C and HDL-C levels were recorded. 
Outcome events characterized were hematoma volume, hematoma expansion, in-hospital 
functional outcome, and in-hospital mortality.  
Results: A total of 672 patients with acute ICH [(mean age 61.6±14.0 years, 43.6% women, 
median ICH score 1 (IQR: 0-2)] were evaluated. Statin pretreatment was not associated with 
neuroimaging or clinical outcomes. Higher LDL-C levels were associated with several markers 
of poor clinical outcome and in-hospital mortality. LDL-C levels were independently and 
negatively associated with the cubed root of hematoma volume (linear regression coefficient -
0.021, 95% CI: -0.042−-0.001; p=0.049) on multiple linear regression models. Higher admission 
LDL-C (OR 0.88, 95% CI 0.77 – 0.99; p= 0.048) was also an independent predictor for 
decreased hematoma expansion. Higher admission LDL-C levels were independently (p <0.001) 
associated with lower likelihood of in-hospital mortality (OR per 10mg/dL increase 0.68, 95% 
CI: 0.57– 0.80) in multivariable logistic regression models.  
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Conclusions: Higher LDL-C levels at hospital admission were an independent predictor for 
lower likelihood of hematoma expansion and decreased in-hospital mortality in patients with 
acute spontaneous ICH. This association requires independent confirmation.  
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Introduction 
The relationship between lipoprotein cholesterol levels [low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)] and clinical outcomes in 
patients with acute intracerebral hemorrhage (ICH) remains controversial. Early epidemiological 
studies suggested an association between lower cholesterol levels and death after stroke 1. 
Subsequent studies further evaluated LDL-C with associations noted between lower LDL-C 
levels and ICH risk 2, hematoma growth 3, and mortality 4-6.  
As the primary agent responsible for lowering lipid levels, the role of statins in ICH 
incidence and hematoma volume expansion has generated controversy. This was particularly 
highlighted after statins were found to be associated with increased rates of hemorrhagic 
transformation in ischemic stroke 7 and higher incidence of cerebral microbleeds in ICH 8. 
However, recent studies have also provided observational evidence showing statin use improving 
clinical outcomes after ICH 9,10 and not increasing the likelihood of cerebral microbleeds 11.  
The relationship between statin use and dosing, lipoprotein levels, hematoma volume, 
and clinical outcome remains unclear due to inconsistencies in the existing literature and failure 
to systematically evaluate both clinical and neuroimaging outcomes in individual patients. To 
clarify this relationship, we sought to evaluate the association of lipoprotein cholesterol levels 
with clinical and neuroimaging outcomes in patients with acute ICH. 
 
Materials and methods 
Patient selection and study protocol 
Institutional review board approval was obtained for the conduct of a prospective cohort 
study evaluating functional and neuroimaging outcomes in adult patients with acute, 
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spontaneous, non-traumatic ICH in a tertiary-care stroke center. All data was prospectively 
collected as per hospital registry protocol for acute (< 24 hours) ICH and retrospectively 
reviewed for accuracy by blinded neurologists (YK, KD, AK, NG). Consecutive patients with 
ICH were initially identified by ICD code, which spanned a five-year period (from January 2011 
to December 2015). Inclusion criteria were as follows: spontaneous etiology for ICH and adult 
age (> 18 years old). Exclusion criteria were as follows: nonspontaneous etiologies of ICH 
(including traumatic ICH, metastatic lesion with associated hemorrhage, ICH resulting from 
venous sinus thrombosis, and ICH resulting from underlying vascular lesions), ICH due to 
supratherapeutic international normalized ratio (INR) in the setting of prehospital anticoagulation 
or coagulopathy (threshold INR > 1.7), and thrombocytopenia (platelets < 50,000/mm3).  
All ICHs were initially admitted to the intensive care unit (ICU). As per hospital 
protocol, patients were treated with intravenous pushes of enalapril, hydralazine, or labetalol and 
escalated to continuous nicardipine infusion to reach a goal SBP < 140 mmHg during the first 24 
hours after admission. If clinically stable, SBP parameters were relaxed to SBP goal < 160 
mmHg after 24 hours of admission. As per hospital protocol and unless contraindicated or on a 
different prehospital statin dose, all patients with ICH were given a medium-dose statin within 
24 hours of admission after swallow evaluation or feeding tube insertion. Intensive statin 
pretreatment was defined as patients taking the maximum dose of their respective statin 12. 
Demographic characteristics, past medical history, premorbid modified Rankin scores 
(mRS), and baseline radiological and clinical parameters were prospectively collected. Baseline 
clinical severity was documented with National Institutes of Health Stroke Scale (NIHSS) 
scores. Clinical outcome endpoints included mRS at discharge, hospital length of stay, and in-
hospital mortality. Favorable functional outcome at discharges was defined as mRS 0-2. All 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
laboratory values—INR, glucose, platelets, LDL-C, HDL-C—were obtained within 24 hours of 
hospitalization.  
 
Mortality analysis 
Causes of mortality were delineated as follows. Cerebral herniation occurred when the 
patient reached a comatose state from herniation, was not formally declared brain dead, and 
passed away from cardiac death after palliative extubation. Brain death occurred when patients 
met clinical criteria which included loss of brainstem reflexes and apnea testing confirmation or 
ancillary testing for cerebral circulatory arrest. Spontaneous cardiac arrest occurred during an 
unanticipated cardiac arrest, unrelated to their primary ICH. Finally, palliative care occurred 
when the patient remained extubated for longer than 24 hours and was transitioned to comfort 
measures with subsequent death.  
 
Imaging characterization: ICH volume, and hematoma expansion 
Follow-up head computed tomography (CTH) was acquired within 6 to 24 hours of initial 
CTH. ICH volume as noted in baseline CTH was measured as delineated by the ABC/2 score 13. 
Hematoma expansion was defined as >33% expansion or >12.5 ml hematoma volume growth on 
serial CT scans taken within a 48-hour span 14-16.  
 
Statistical analysis 
We presented continuous parametric data using their mean values together with their 
corresponding standard deviations (SDs). We used median values with their corresponding 
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interquartile ranges (IQR) for the presentation of non-parametric data and percentages for all 
dichotomous variables.  
Univariate and multivariate regression analyses were used to evaluate the associations 
between baseline characteristics and admission hematoma volume, hematoma expansion, 
functional dependence at hospital discharge (mRS scores 3-6), in-hospital mortality among 
included patients. In all univariate analyses, a threshold of p <0.1 was used to identify candidate 
variables for inclusion in multivariate regression models that tested statistical significance 
hypothesis using the likelihood ratio test with an alpha value of 0.05 17. We reported all 
associations as linear regression coefficients in linear regression models and odds ratios (ORs) in 
logistic regression models, respectively, with their corresponding 95% confidence intervals (95% 
CI). In all simple and multiple linear regression analyses, baseline hematoma volume was cube 
root transformed for each patient to satisfy statistical assumptions regarding normality of the 
distribution, as previously described 18. The Stata Statistical Software Release 13 for Windows 
(College Station, TX, StataCorp LP) was used for all statistical analyses. 
 
Results 
 A total of 803 patients were identified as ICH by ICD code; of these patients, 672 met 
inclusion criteria [mean age 61.6 ±14.0 years, 43.6% women, median ICH score 1 (IQR: 0-2)]. 
Baseline characteristics for the study population are included in Table 1. Prehospital statin use 
was documented in 25.8% and prehospital intensive statin use was documented in 3.4% of the 
study population (mean admission LDL-C: 100.3 ±36.3 mg/dl; mean admission HDL-C: 52.6 
±18.6 mg/dl).  
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Associations between demographic variables and the cubed root of hematoma volume at 
admission are shown in Table 2. Several demographic variables were associated with cubed root 
of hematoma volume on simple linear regression analysis: Caucasian race, history of 
hypertension, history of hyperlipidemia, coronary artery disease, past history of stroke, 
admission glucose, admission LDL-C, subcortical location for ICH, admission systolic blood 
pressure (SBP), and admission NIHSS. Multiple linear regression analyses identified the 
following independent predictors of admission hematoma volume: history of stroke, admission 
LDL-C, subcortical location of ICH, and admission NIHSS. More specifically, LDL-C levels (p= 
0.049) were independently and negatively associated with the cubed root of hematoma volume 
(linear regression coefficient:-0.021, 95% CI -0.042 – -0.001) on hematoma volumes after 
adjusting for potential confounders.  
  The following variables were related to hematoma expansion on initial univariate logistic 
regression models (Table 3): Caucasian race, history of coronary artery disease, admission LDL-
C, and admission hemoglobin A1c. However, only higher admission LDL-C emerged as an 
independent predictor of lower likelihood of hematoma expansion on multivariate logistic 
regression analyses (OR per 10mg/dL increase: 0.88, 95% CI 0.77 – 0.99, p= 0.048).   
 Table 4 shows the univariate and multivariate associations of baseline characteristics with 
functional dependence (mRS-scores of 3-6) at hospital discharge. The following four variables 
were independently related to functional outcome at hospital discharge: age, history of smoking, 
admission SBP, and admission NIHSS. Although admission LDL-C was associated with 
functional independence in initial univariate analyses, the former association did not retain its 
statistical significance in multivariate logistic regression models (OR 0.94, 95% CI 0.86 – 1.02, 
p= 0.153). 
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 Table 5 shows the univariate and multivariate associations of baseline characteristics with 
in-hospital mortality. The following four variables emerged as independent predictors of in-
hospital mortality: history of chronic kidney disease, admission LDL-C, admission HDL-C, and 
admission NIHSS. Higher admission LDL-C levels were independently associated (p <0.001) 
with lower likelihood of in-hospital mortality (OR per 10mg/dL increase: 0.68, 95% CI 0.57 – 
0.80) in multivariate logistic regression analyses adjusting for potential confounders (Table 5). 
Every 10 mg/dl increase in admission LDL-C was related to a decrease in the odds of in-hospital 
mortality by 32% (95% CI: 20%-43%). 
 
Discussion 
The greatest uncertainty regarding the association between lipoprotein levels, statin use, 
and clinical outcomes in acute ICH, center around the lipoprotein lowering effects of statins 
weighed against their neuroprotective, anti-inflammatory effects. We chose to evaluate these 
potential predictors simultaneously—lipoprotein levels and statin dosage—and identified several 
independent associations using the following clinical outcome variables: initial hematoma 
volume, hematoma expansion, functional independence at hospital discharge, and mortality at 
hospital discharge. 
First, statin pretreatment and prehospital intensive statin use was not associated with any 
of the clinical outcomes in our analyses. A trend associating statin use with higher odds of 
functional independence at hospital discharge was noted, but this relationship did not reach 
statistical significance. As larger meta-analyses, published since SPARCL 7 have shown statin 
use to be associated with reduced mortality in ICH 9,10, our study may have been underpowered 
to detect a similar association. However, our findings are in line with more recent studies that 
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failed to document any association between statin pretreatment and admission hematoma volume 
or hematoma expansion 19. This somewhat unexpected finding suggests a lesser influence on the 
neuroprotective and anti-inflammatory effects of statins that promote clinical outcome after 
ischemic strokes 20. As LDL-C and to some extent HDL-C, had more robust associations with 
clinical outcomes, this questions whether lipoprotein cholesterol levels, rather than prehospital 
statin use, play a larger role in clinical outcomes after ICH. 
Second, in accordance with prior studies, we found higher LDL-C levels associated with 
smaller hematoma volumes, smaller probability of hematoma expansion, and lower mortality. 
The mechanism for the role of higher LDL-C in preventing mortality may lie in these 
associations as hematoma expansion 16 and larger initial hematoma volume 21 are well-known 
predictors of mortality after ICH. Potential unifying chronic and dynamic mechanisms may 
account for these associations. One potential chronic unifying mechanism may be the association 
of LDL-C with lower presence of cerebral microbleeds 22. Cerebral microbleeds and their 
relationship with LDL-C may ultimately link all of these associations because they negatively 
impact clinical outcomes in patients with ICH by promoting hematoma growth 3, recurrent ICH 
23
 and larger perihematomal edema volumes 24. More dynamically, longitudinal studies of 
lipoprotein levels show a decline in LDL-C preceding spontaneous ICH 25, which further 
suggests that LDL-C levels rather than prehospital statin use play a more definitive mechanistic 
role in ICH incidence and outcome.  
HDL-C levels provided less consistent results as HDL-C was not associated with 
hematoma expansion or clinical outcome at hospital discharge, but were associated with lower 
mortality. Although lower HDL-C levels have been associated with increased ICH incidence 
26,27
, the question of ICH incidence was not within the scope of this study.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Several limitations of the present study need to be acknowledged. First, clinical outcomes 
(mRS and mortality) were evaluated at discharge and not in a prolonged subacute time frame to 
maximize clinical recovery after ICH. However, a subsequent three month follow-up evaluation 
would have likely improved functional outcome as it would reflect clinical improvements made 
after rehabilitation and physical therapy. Second, data was collected retrospectively in a single 
tertiary care center and this may have introduced bias. However, variables were prospectively 
inputted and were included in larger database in which study personnel was blinded to the study 
hypothesis. Finally, although the role of statin use was evaluated, a complex interplay of 
mechanisms preclude definitive relationships being made between statin use, lipoprotein levels, 
and clinical outcomes. These include the association between statin use and genetic 
polymorphisms in effecting lipoprotein levels 28, effects of complementary enzymes such as 
acetylcholinesterase and butyrylcholinoesterase in lowering lipoprotein levels 29, and pleiotropic 
effects of statins including anti-inflammation and angiogenesis 30.  
 In conclusion, this study highlights that higher LDL-C levels are associated with lower 
in-hospital mortality in patients with spontaneous ICH. Potential underlying mechanisms of this 
association may be related to the smaller hematoma volumes and lower likelihood of hematoma 
expansion that was documented in patients with higher admission LDL-C. Pre-hospital and acute 
statin intake was not associated with clinical outcome in our dataset. Larger, prospective, 
multicenter studies further delineating the role of statins and the mechanism between increased 
LDL-C levels and lower mortality are necessary to independently validate these findings.  
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Figure Legends  
 
Figure 1. Scatterplot and regression line demonstrating the inverse relationship between the 
cubed root of baseline hematoma volumes and admission low-density lipoprotein cholesterol 
levels for patients with intracerebral hemorrhage.  
 
Figure 2. Bar charts and fractional-polynomial prediction line demonstrating the inverse 
relationship between all-cause mortality frequency and admission low-density lipoprotein 
cholesterol levels (per 10 unit increase) in patients with intracerebral hemorrhage.  
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Tables 
 
Table 1: Baseline characteristics of the study population (n=672). 
Age (years, mean ±SD) 61.6±14.0 
Gender (% female) 43.6% 
Race (%) Caucasian: 27.8% 
Black: 70.5% 
Asian: 1% 
Hispanic: 0.7% 
BMI (mean ±SD) 28.9±7.4 
ICH score (median, IQR) 1 (0-2) 
Mortality (%) 24.1% 
Hypertension (%) 86% 
Diabetes mellitus (%) 34.8% 
Hyperlipidemia (%) 32.4% 
Coronary artery disease (%) 12.3% 
Congestive heart failure (%) 7.6% 
Chronic kidney disease (%) 13.9% 
History of stroke (%) 22.6% 
Smoking (%) 39.8% 
Antiplatelet pretreatment (%) 32.1% 
Anticoagulant pretreatment (%) 3.8% 
Statin pretreatment (%) 25.8% 
Intensive statin pretreatment (%) 3.4% 
Admission INR (mean ±SD) 1.11±0.37 
Admission glucose (median, IQR) 132 (104-174) 
Admission platelets (x1,000, (median, IQR)) 217 (177-267) 
Admission low-density liprotein cholesterol (mg/dl,  mean ±SD) 100.3±36.3 
Admission high-density liprotein cholesterol (mg/dl,  mean ±SD) 52.6±18.6 
Admission hemoglobin A1c (%, median, IQR) 5.7 (5.3-6.4) 
Admission Creatinine (median, IQR) 1.1 (0.8-1.4) 
Subcortical ICH a (%) 69.8% 
Admission systolic blood pressure (mmHg,  mean ±SD) 183±40 
Admission diastolic blood pressure (mmHg,  mean ±SD) 103±27 
Admission NIHSS b score (median, IQR) 8 (2-18) 
a ICH,  intracerebral hemorrhage. 
b NIHSS, National Institutes of Health Stroke Scale. 
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Table 2: Simple and multiple linear regression analyses evaluating the association of baseline 
characteristics with the cubed root of baseline hematoma volume. 
 Simple linear regression 
analysis 
Multiple linear regression 
analysis 
Variable Coefficient (95% CI) p Coefficient (95% CI) p 
Age 0.003 (-0.002, 0.008) 0.23 - - 
Gender -0.120 (-0.27, 0.028)  0.11 - - 
Caucasian race 0.194 (0.029, 0.36) 0.021 0.15 (-0.024, 0.33) 0.089 
BMI -0.001 (-0.011, 0.009) 0.83 - - 
Hypertension 0.216 (0.004, 0.43) 0.046 0.002 (-0.22, 0.23) 0.99 
Diabetes mellitus 0.065 (-0.090, 0.22) 0.41 - - 
Hyperlipidemia -0.245 (-0.40, -0.087) 0.002 -0.062 (-0.22, 0.095)  0.44 
Coronary artery disease 0.249 (0.026, 0.47) 0.028 -0.016 (-0.26, 0.23) 0.90 
Congestive heart failure 0.180 (-0.095, 0.455) 0.20 - - 
Chronic kidney disease -0.035 (-0.25, 0.18) 0.75 - - 
History of stroke -0.257 (-0.43, -0.082) 0.004 -0.26 (-0.44, -0.088) 0.003 
Smoking 0.025 (-1.012, 0.15) 0.70 - - 
Antiplatelet  0.089 (-0.072, 0.25) 0.28 - - 
Anticoagulant 0.115 (-0.27, 0.51) 0.56 - - 
Statin pretreatment -0.073 (-0.25, 0.10) 0.41 - - 
Intensive Statin pretreatment 0.391 (-0.676, 0.849) 0.10 - - 
Admission INR 0.099 (-0.12, 0.32) 0.37 - - 
Admission glucose a 0.001 (0.001, 0.002) <0.001 -0.001 (-0.002, 0.001) 0.57 
Admission platelets -0.001 (-0.002, 0.001) 0.18 - - 
Admission low-density liprotein 
cholesterol a 
-0.040 (-0.065, -0.016) 0.001 -0.021 (-0.042, -0.001) 0.049 
Admission high-density liprotein 
cholesterol a 
-0.037 (-0.085, 0.010) 0.12 - - 
Admission hemoglobin A1c -0.014 (-0.69, 0.041) 0.62 - - 
Admission creatinine -0.012 (-0.056, 0.033) 0.61 - - 
Subcortical intracerebral 
hemorrhage  
-0.360 (-0.52, -0.20) <0.001 -0.545 (-0.71, -0.38) <0.001 
Admission systolic blood pressure a 0.020 (0.002, 0.039) 0.031 0.012 (-0.010, 0.034) 0.29 
Admission diastolic blood pressurea 0.008 (-0.019, 0.034) 0.58 - - 
Admission NIHSS b 0.043 (0.038, 0.049) <0.001 0.048 (0.039, 0.056) <0.001 
a Per 1mg/dL increase. 
b NIHSS,  National Institutes of Health Stroke Scale. 
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Table 3: Univariate and multivariate logistic regression analyses evaluating the association of 
baseline characteristics with the likelihood of hematoma expansion. 
 Univariate logistic 
Regression Analysis 
Multivariate logistic 
Regression Analysis 
Variable OR (95%CI) p OR (95%CI) p 
Age 1.01 (0.98, 1.02) 0.64 - - 
Gender 0.84 (0.49, 1.44) 0.53 - - 
Caucasian Race 1.61 (0.92, 2.83) 0.096 1.28 (0.52, 3.14) 0.58 
BMI 0.99 (0.96, 1.03) 0.83 - - 
Hypertension 1.17 (0.52, 2.61) 0.70 - - 
Diabetes mellitus 0.91 (0.53, 1.57) 0.74 - - 
Hyperlipidemia 1.21 (0.69, 2.11) 0.50 - - 
Coronary artery disease 2.71 (1.40, 5.27) 0.003 1.93 (0.63, 5.85) 0.25 
Congestive heart failure 1.52 (0.63, 3.69) 0.35 - - 
Chronic kidney disease 0.93 (0.43, 2.00) 0.85 - - 
History of stroke 0.90 (0.48, 1.68) 0.73 - - 
Smoking 1.03 (0.65, 1.64) 0.89 - - 
Antiplatelet  0.97 (0.55, 1.70) 0.91 - - 
Anticoagulant 1.24 (0.26, 5.97) 0.79 - - 
Statin pretreatment 1.35 (0.76, 2.41) 0.31 - - 
Intensive statin pretreatment 0.46 (0.05, 3.86) 0.472 - - 
Admission INR 0.93 (0.41, 2.10) 0.85 - - 
Admission glucose a 1.00 (0.99, 1.01) 0.68 - - 
Admission platelets 0.97 (0.55, 1.70) 0.91 - - 
Admission low-density liprotein 
cholesterol a 
0.91 (0.82, 1.01) 0.052 0.88 (0.77, 0.99) 0.048 
Admission high-density liprotein 
cholesterol a 
1.05 (0.89, 1.24) 0.53 - - 
Admission hemoglobin A1c 1.18 (0.98, 1.41) 0.073 1.15 (0.93, 1.43) 0.19 
Admission Creatinine 0.96 (0.79, 1.17) 0.70 - - 
Subcortical intracerebral hemorrhage 1.49 (0.80, 2.77) 0.21 - - 
Admission systolic blood pressure a 0.97 (0.90, 1.04) 0.36 - - 
Admission diastolic blood pressure a 0.95 (0.86, 1.05) 0.35 - - 
Admission NIHSSb 1.00 (0.97, 1.03) 0.86 - - 
a per 10mg/dL increase 
b NIHSS – National Institutes of Health Stroke Scale 
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Table 4. Univariate and multivariate logistic regression analyses evaluating the association of 
baseline characteristics with the likelihood of functional dependence at hospital discharge (mRS-
scores of 3-6). 
 Univariate logistic 
Regression Analysis 
Multivariate logistic 
Regression Analysis 
Variable OR (95%CI) p OR (95%CI) p 
Age 1.02 (1.01, 1.03) 0.004 1.03 (1.00, 1.07) 0.023 
Gender 1.14 (0.82, 1.58) 0.44 - - 
Caucasian Race 0.92 (0.64, 1.32) 0.65 - - 
BMI 0.98 (0.96, 1.01) 0.11 - - 
Hypertension 1.79 (1.14, 2.80) 0.011 0.88 (0.39, 2.00) 0.77 
Diabetes mellitus 1.15 (0.82, 1.63) 0.41 - - 
Hyperlipidemia 0.77 (0.54, 1.09) 0.15 - - 
Coronary artery disease 1.17 (0.70, 1.95) 0.54 - - 
Congestive heart failure 2.03 (0.99, 4.14) 0.052 2.31 (0.55, 9.66) 0.25 
Chronic kidney disease 0.75 (0.47, 1.18) 0.21 - - 
History of stroke 1.07 (0.72, 1.58) 0.75 - - 
Smoking 1.37 (1.02, 1.84) 0.036 2.47 (1.33, 4.57) 0.004 
Antiplatelet  1.38 (0.96, 1.98) 0.081 1.43 (0.73, 2.82) 0.30 
Anticoagulant 0.61 (0.27, 1.37) 0.24 - - 
Statin pretreatment 1.40 (0.95, 2.08) 0.090 1.99 (0.95, 4.14) 0.066 
Intensive statin pretreatment 0.93 (0.35, 2.43) 0.880 - - 
Admission INR 0.84 (0.54, 1.29) 0.42 - - 
Admission glucose a 1.01 (1.00, 1.02) 0.001 1.00 (0.99, 1.01) 0.72 
Admission platelets 1.00 (0.99, 1.01) 0.44 - - 
Admission low-density liprotein 
cholesterol a 
0.91 (0.86, 0.96) 0.001 0.94 (0.86, 1.02) 0.15 
Admission high-density liprotein 
cholesterol a 
1.05 (0.94, 1.17) 0.36 - - 
Admission hemoglobin A1c 0.96 (0.84, 1.09) 0.53 - - 
Admission Creatinine 0.98 (0.89, 1.08) 0.73 - - 
Subcortical intracerebral hemorrhage 1.71 (1.21, 2.42) 0.002 1.12 (0.57, 2.21) 0.74 
Admission systolic blood pressure a 1.08 (1.04, 1.13) <0.001 1.18 (1.03, 1.36) 0.016 
Admission diastolic blood pressure a 1.07 (1.01, 1.13) 0.033 0.89 (0.72, 1.10) 0.29 
Admission NIHSS b 1.41 (1.33, 1.51)  <0.001 1.41 (1.30, 1.54) <0.001 
a per 10mg/dL increase 
b NIHSS – National Institutes of Health Stroke Scale 
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Table 5. Univariate and multivariate logistic regression analyses evaluating the association of 
baseline characteristics with the likelihood of in-hospital mortality.  
 
 Univariate logistic 
Regression Analysis 
Multivariate logistic 
Regression Analysis 
Variable OR (95%CI) p OR (95%CI) p 
Age 1.00 (0.99, 1.01) 0.80 - - 
Gender 0.95 (0.66, 1.35) 0.77 - - 
Caucasian Race 1.08 (0.73, 1.58) 0.70 - - 
BMI 0.97 (0.95, 1.01) 0.063 1.00 (0.94, 1.07) 0.927 
Hypertension 1.75 (0.98, 3.14) 0.059 2.03 (0.28, 14.8) 0.486 
Diabetes mellitus 0.98 (0.67, 1.42) 0.91 - - 
Hyperlipidemia 0.55 (0.37, 0.84) 0.006 1.01 (0.36, 2.82)  0.981 
Coronary artery disease 1.94 (1.18, 3.18) 0.008 1.86 (0.47, 7.43) 0.378 
Congestive heart failure 2.24 (1.24, 4.06) 0.008 1.28 (0.28, 5.89) 0.753 
Chronic kidney disease 1.90 (1.18, 3.05) 0.008 5.81 (1.42, 23.8) 0.014 
History of stroke 0.72 (0.46, 1.13) 0.16 - - 
Smoking 1.44 (1.07, 1.94) 0.017 1.59 (0.79, 3.20) 0.188 
Antiplatelet  1.17 (0.80, 1.72) 0.41 - - 
Anticoagulant 1.88 (0.81, 4.35) 0.14 - - 
Statin pretreatment 0.91 (0.60, 1.39) 0.67 - - 
Intensive statin pretreatment 0.68 (0.22, 2.16) 0.517 - - 
Admission INR 1.33 (0.85, 2.10) 0.22 - - 
Admission glucose a 1.01 (1.00, 1.02) <0.001 1.00 (0.99, 1.01) 0.951 
Admission platelets 1.00 (0.99, 1.01) 0.80 - - 
Admission low-density liprotein 
cholesterol a 
0.76 (0.68, 0.84) <0.001 0.96 (0.94, 0.98) <0.001 
Admission high-density liprotein 
cholesterol a 
0.84 (0.71, 1.01) 0.057 0.97 (0.94, 0.99) 0.011 
Admission hemoglobin A1c 0.94 (0.77, 1.15) 0.54 - - 
Admission Creatinine 1.22 (1.11, 1.35) <0.001 0.86 (0.63, 1.17) 0.341 
Subcortical intracerebral hemorrhage 1.35 (0.90, 2.01) 0.147 - - 
Admission systolic blood pressure a 1.07 (1.02, 1.12) 0.003 1.00 (0.99, 1.02) 0.746 
Admission diastolic blood pressure a 1.05 (0.99, 1.12) 0.10 - - 
Admission NIHSS b 1.21 (1.17, 1.24) <0.001 1.24 (1.17, 1.33) <0.001 
a per 10mg/dL increase  
b NIHSS – National Institutes of Health Stroke Scale 
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Highlights – Atherosclerosis 
• The relationship between lipoproteins (LDL, HDL) and outcome in ICH is unclear 
• This relationship was studied in a prospective cohort study with 672 patients 
• Higher LDL levels were independently associated with lower in-hospital mortality 
  
 
